Appia Bio, Inc

Appia Bio, Inc is a biotechnology company focused on developing innovative allogeneic cell therapies, leveraging engineered T cells to target various forms of cancer. Founded in 2020 and headquartered in Los Angeles, US, Appia Bio develops unique T cell therapies for cancer treatment. The company raised USD 52. 00 mn in Series A funding on May 11, 2021, led by 8VC with participation from Two Sigma Ventures, Sherpa Healthcare Partners, and Freeflow Ventures.

CEO Jeenjoo Kang has prior experience in biotechnology ventures. Appia Bio specializes in developing universal allogeneic cell therapies utilizing invariant NKT and gamma delta T cells. These therapies are designed to target various cancers, offering potential curative solutions by leveraging the unique properties of engineered T cells. The company's core product offerings are based on a technology platform that combines stem cell biology with advanced T cell development techniques.

Appia Bio aims to provide accessible treatments to patients, ensuring effective delivery in clinical settings, primarily catering to oncology markets in North America and Europe. Appia Bio’s revenue model is structured around partnerships and collaborations with medical institutions and research organizations that seek cancer therapies. The company engages in business-to-business transactions, where healthcare providers enter agreements to utilize Appia Bio's engineered T cell therapies as part of their treatment regimens, with pricing determined through negotiated contracts based on specific needs. Appia Bio plans to utilize the USD 52.

00 mn raised in Series A funding to rapidly build out its CAR-iNKT pipeline and establish the clinical potential of its ACUA platform. The company is targeting expansion into new markets, with a focus on regions in Europe and Asia, aiming for significant progress by 2023. Additionally, Appia Bio is working on launching new products designed to enhance treatment options for cancer patients.